+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anemia in Chronic Kidney Disease Market and Forecast Analysis to 2035

  • ID: 3797405
  • Report
  • 318 pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
Chronic kidney disease (CKD) is characterized by decreased kidney function and kidney damage. Damaged renal tissue has a diminished ability to produce erythropoietin, a hormone that stimulates red blood cell production. Consequently, patients with CKD often experience anemia, defined as a reduction in red blood cells or hemoglobin levels. The risk of anemia increases as CKD progresses and kidney function declines.

Market Snapshot
  • The launch of novel HIF inhibitor roxadustat will offset biosimilar erosion of Epogen to drive market growth.
  • Physicians expect to switch a significant portion of patients on stable erythropoiesis-stimulating agent (ESA) therapy to oral ESAs within three years of their launch.
  • By 2037, there will be an estimated 28% increase in total prevalent cases in the US, Japan, and five major EU markets.
  • Use of erythropoiesis-stimulating agents, the standard of care for anemia in CKD, may decline due to cost and safety concerns.
  • Pipeline therapies plan to capture market share by reducing costs and safety concerns associated with treatment.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 11 January 2018)
Overview
Executive Summary
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Product Profile: Aranesp
Product Profile: Auryxia
Product Profile: Dexferrum
Product Profile: Epogen
Product Profile (Late Stage): Feraccru
Product Profile: Feraheme
Product Profile: Injectafer
Product Profile: Mircera
Product Profile: Neorecormon
Product Profile: Venofer
Product Profile (Late Stage): Roxadustat

TREATMENT: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 09 March 2016)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Country Treatment Trees
Current Treatment Options
Prescribing Trends
Unmet Needs In Anemia In Chronic Kidney Disease
Future Treatment

EPIDEMIOLOGY: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 17 July 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography

MARKETED DRUGS: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 11 January 2018)
Overview
Executive Summary
Product Overview
Product Profile: Aranesp
Product Profile: Auryxia
Product Profile: Dexferrum
Product Profile: Epogen
Product Profile: Feraheme
Product Profile: Injectafer
Product Profile: Mircera
Product Profile: Neorecormon
Product Profile: Venofer

PIPELINE: ANEMIA IN CHRONIC KIDNEY DISEASE (Published on 11 January 2018)
Overview
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Feraccru
Product Profile (Late Stage): Roxadustat

LIST OF FIGURES
Figure 1: Anemia in chronic kidney disease – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for anemia in chronic kidney disease
Figure 3: Anemia in chronic kidney disease market sales across the US, Japan, and five major EU markets, by country, 2015–24
Figure 4: Sales of ESAs and roxadustat in the US, Japan, and five major EU markets, by drug, 2015–24
Figure 5: Anemia in chronic kidney disease market sales in the US, Japan, and five major EU markets, by class, 2015–24
Figure 6: Sales of Epogen and biosimilar epoetin alfa in the US, Japan, and five major EU markets, by drug, 2015–24
Figure 7: Sales of biosimilar epoetin alfa in the US, Japan, and five major EU markets, by country, 2015–24
Figure 8: Sales of iron supplements in anemia in chronic kidney disease in the US, Japan, and five major EU markets, by drug, 2015–24
Figure 9: Patient-based forecast methodology for anemia in chronic kidney disease
Figure 10: Price sources and calculations, by country
Figure 11: Aranesp for anemia in chronic kidney disease – SWOT analysis
Figure 12: The authors drug assessment summary of Aranesp for anemia in chronic kidney disease
Figure 13: The authors drug assessment summary of Aranesp for anemia in chronic kidney disease
Figure 14: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
Figure 15: Auryxia for anemia in chronic kidney disease – SWOT analysis
Figure 16: The authors drug assessment summary of Auryxia for anemia in chronic kidney disease
Figure 17: The authors drug assessment summary of Auryxia for anemia in chronic kidney disease
Figure 18: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
Figure 19: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country, 2015–24
Figure 20: Epogen for anemia in chronic kidney disease – SWOT analysis
Figure 21: The authors drug assessment summary of Epogen for anemia in chronic kidney disease
Figure 22: The authors drug assessment summary of Epogen for anemia in chronic kidney disease
Figure 23: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015–24
Figure 24: Feraccru for anemia in chronic kidney disease – SWOT analysis
Figure 25: The authors drug assessment summary of Feraccru for anemia in chronic kidney disease
Figure 26: The authors drug assessment summary of Feraccru for anemia in chronic kidney disease
Figure 27: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
Figure 28: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015–24
Figure 29: Injectafer for anemia in chronic kidney disease – SWOT analysis
Figure 30: The authors drug assessment summary of Injectafer for anemia in chronic kidney disease
Figure 31: The authors drug assessment summary of Injectafer for anemia in chronic kidney disease
Figure 32: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country, 2015–24
Figure 33: Mircera for anemia in chronic kidney disease – SWOT analysis
Figure 34: The authors drug assessment summary of Mircera for anemia in chronic kidney disease
Figure 35: The authors drug assessment summary of Mircera for anemia in chronic kidney disease
Figure 36: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
Figure 37: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015–24
Figure 38: Venofer for anemia in chronic kidney disease – SWOT analysis
Figure 39: The authors drug assessment summary of Venofer for anemia in chronic kidney disease
Figure 40: The authors drug assessment summary of Venofer for anemia in chronic kidney disease
Figure 41: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
Figure 42: Roxadustat for anemia in chronic kidney disease – SWOT analysis
Figure 43: The authors drug assessment summary of roxadustat for anemia in chronic kidney disease
Figure 44: The authors drug assessment summary of roxadustat for anemia in chronic kidney disease
Figure 45: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
Figure 46: Physician-estimated rate of diagnosis of anemia in chronic kidney disease, by country (%)
Figure 47: Proportion of anemia in chronic kidney disease patients at each grade of disease, by country (%)
Figure 48: Proportion of patients with anemia in chronic kidney disease receiving treatment from each physician type, by country (%)
Figure 49: Proportion of patients with mild anemia receiving each treatment type, by country (%)
Figure 50: Proportion of patients with moderate anemia receiving each treatment type, by country (%)
Figure 51: Proportion of patients with severe anemia receiving each treatment type, by country (%)
Figure 52: Proportion of patients with very severe anemia receiving each treatment type, by country (%)
Figure 53: Proportion of patients prescribed top five pharmacological treatments, by country (%)
Figure 54: Percentage of anemia in chronic kidney disease patients on pharmacological treatment receiving each ESA (alone or in combination), by country
Figure 55: Percentage of anemia in chronic kidney disease patients on pharmacological treatment receiving each iron supplement (alone or in combination), by country
Figure 56: Average length of iron supplement treatment, by anemia grade (days)
Figure 57: Expected epoetin alfa biosimilar use in new patients compared to physician-reported use in the 5EU and Japan, by country (%)
Figure 58: Expected epoetin alfa biosimilar use in patients currently receiving epoetin alfa compared to physician-reported use in the 5EU and Japan, by country (%)
Figure 59: Newly diagnosed patients expected to be prescribed an oral ESA, one and three years post-launch, by country (%)
Figure 60: Patients on stable ESA therapy expected to be switched to an oral ESA, one and three years post-launch, by country (%)
Figure 61: Trends in total prevalent cases of anemia in CKD in the US, Japan, and five major EU markets, by country, 2017–37
Figure 62: Aranesp for anemia in chronic kidney disease – SWOT analysis
Figure 63: The authors drug assessment summary of Aranesp for anemia in chronic kidney disease
Figure 64: The authors drug assessment summary of Aranesp for anemia in chronic kidney disease
Figure 65: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
Figure 66: Auryxia for anemia in chronic kidney disease – SWOT analysis
Figure 67: The authors drug assessment summary of Auryxia for anemia in chronic kidney disease
Figure 68: The authors drug assessment summary of Auryxia for anemia in chronic kidney disease
Figure 69: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
Figure 70: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country, 2015–24
Figure 71: Epogen for anemia in chronic kidney disease – SWOT analysis
Figure 72: The authors drug assessment summary of Epogen for anemia in chronic kidney disease
Figure 73: The authors drug assessment summary of Epogen for anemia in chronic kidney disease
Figure 74: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015–24
Figure 75: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country, 2015–24
Figure 76: Injectafer for anemia in chronic kidney disease – SWOT analysis
Figure 77: The authors drug assessment summary of Injectafer for anemia in chronic kidney disease
Figure 78: The authors drug assessment summary of Injectafer for anemia in chronic kidney disease
Figure 79: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country, 2015–24
Figure 80: Mircera for anemia in chronic kidney disease – SWOT analysis
Figure 81: The authors drug assessment summary of Mircera for anemia in chronic kidney disease
Figure 82: The authors drug assessment summary of Mircera for anemia in chronic kidney disease
Figure 83: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24

LIST OF TABLES
Figure 84: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country, 2015–24
Figure 85: Venofer for anemia in chronic kidney disease – SWOT analysis
Figure 86: The authors drug assessment summary of Venofer for anemia in chronic kidney disease
Figure 87: The authors drug assessment summary of Venofer for anemia in chronic kidney disease
Figure 88: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
Figure 89: Feraccru for anemia in chronic kidney disease – SWOT analysis
Figure 90: The authors drug assessment summary of Feraccru for anemia in chronic kidney disease
Figure 91: The authors drug assessment summary of Feraccru for anemia in chronic kidney disease
Figure 92: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
Figure 93: Roxadustat for anemia in chronic kidney disease – SWOT analysis
Figure 94: The authors drug assessment summary of roxadustat for anemia in chronic kidney disease
Figure 95: The authors drug assessment summary of roxadustat for anemia in chronic kidney disease
Figure 96: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
Table 1: Summary of drug classes and molecules included in The authors anemia in chronic kidney disease patient-based forecast
Table 2: Exchange rates used for calculating prices
Table 3: Hematologists and nephrologists surveyed for the anemia in chronic kidney disease primary research study, 2015
Table 4: Aranesp drug profile
Table 5: Aranesp pivotal trial data in anemia in chronic kidney disease
Table 6: Aranesp other late-phase trial data in anemia in chronic kidney disease
Table 7: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 8: Auryxia drug profile
Table 9: Auryxia Phase III data in anemia in chronic kidney disease
Table 10: Auryxia Phase II data in anemia in chronic kidney disease
Table 11: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 12: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country ($m), 2015–24
Table 13: Epogen drug profile
Table 14: Epogen pivotal trial data in anemia in chronic kidney disease
Table 15: Epogen other late-phase trial data in anemia in chronic kidney disease
Table 16: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015–24
Table 17: Feraccru drug profile
Table 18: Feraccru Phase III trials in anemia in chronic kidney disease
Table 19: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 20: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015–24
Table 21: Injectafer drug profile
Table 22: Injectafer Phase III data in anemia in chronic kidney disease
Table 23: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country ($m), 2015–24
Table 24: Mircera drug profile
Table 25: Mircera pivotal trial data in anemia in chronic kidney disease
Table 26: Mircera late-phase trial data in anemia in chronic kidney disease
Table 27: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 28: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015–24
Table 29: Venofer drug profile
Table 30: Venofer pivotal trial data in anemia in chronic kidney disease
Table 31: Venofer late-phase trial data in anemia in chronic kidney disease
Table 32: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 33: Roxadustat drug profile
Table 34: Roxadustat Phase III trials in anemia in chronic kidney disease
Table 35: Roxadustat Phase II and III data in anemia in chronic kidney disease
Table 36: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 37: Nephrologists and hematologists surveyed for the anemia in chronic kidney disease primary research study, November 2015
Table 38: Grades of anemia in chronic kidney disease and corresponding hemoglobin levels
Table 39: Treatments available for anemia in chronic kidney disease across the US, Japan, and five major EU markets
Table 40: Definitions applied for anemia case ascertainment
Table 41: Definition applied for CKD case ascertainment and severity segmentation
Table 42: Sources used for the epidemiological analysis of anemia in CKD in the US, Japan, and five major EU markets, by country
Table 43: Total prevalent cases of anemia in CKD in the US, Japan, and five major EU markets, by country, 2017–37
Table 44: Key marketed drugs for anemia in chronic kidney disease
Table 45: Aranesp drug profile
Table 46: Aranesp pivotal trial data in anemia in chronic kidney disease
Table 47: Aranesp other late-phase trial data in anemia in chronic kidney disease
Table 48: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 49: Auryxia drug profile
Table 50: Auryxia Phase III data in anemia in chronic kidney disease
Table 51: Auryxia Phase II data in anemia in chronic kidney disease
Table 52: Auryxia sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 53: Dexferrum sales for anemia in chronic kidney disease across the five major EU markets, by country ($m), 2015–24
Table 54: Epogen drug profile
Table 55: Epogen pivotal trial data in anemia in chronic kidney disease
Table 56: Epogen other late-phase trial data in anemia in chronic kidney disease
Table 57: Epogen sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015–24
Table 58: Feraheme sales for anemia in chronic kidney disease across the US, Japan, and major EU markets, by country ($m), 2015–24
Table 59: Injectafer drug profile
Table 60: Injectafer Phase III data in anemia in chronic kidney disease
Table 61: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country ($m), 2015–24
Table 62: Mircera drug profile
Table 63: Mircera pivotal trial data in anemia in chronic kidney disease
Table 64: Mircera late-phase trial data in anemia in chronic kidney disease
Table 65: Mircera sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 66: NeoRecormon sales for anemia in chronic kidney disease across Japan and the five major EU markets, by country ($m), 2015–24
Table 67: Venofer drug profile
Table 68: Venofer pivotal trial data in anemia in chronic kidney disease
Table 69: Venofer late-phase trial data in anemia in chronic kidney disease
Table 70: Venofer sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 71: Phase III pipeline products in development for anemia in chronic kidney disease
Table 72: Feraccru drug profile
Table 73: Feraccru Phase III trials in anemia in chronic kidney disease
Table 74: Feraccru sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 75: Roxadustat drug profile
Table 76: Roxadustat Phase III trials in anemia in chronic kidney disease
Table 77: Roxadustat Phase II and III data in anemia in chronic kidney disease
Table 78: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll